1. Inhibition of the Cell Uptake of Delta and Omicron SARS-CoV-2 Pseudoviruses by N -Acetylcysteine Irrespective of the Oxidoreductive Environment.
- Author
-
La Maestra S, Garibaldi S, Balansky R, D'Agostini F, Micale RT, and De Flora S
- Subjects
- Humans, SARS-CoV-2, Acetylcysteine pharmacology, Hydrogen Peroxide pharmacology, Reactive Oxygen Species, Antioxidants pharmacology, HEK293 Cells, Peptidyl-Dipeptidase A metabolism, Ascorbic Acid pharmacology, Oxidants pharmacology, Sulfhydryl Compounds pharmacology, Angiotensin-Converting Enzyme 2, COVID-19 Drug Treatment
- Abstract
The binding of SARS-CoV-2 spikes to the cell receptor angiotensin-converting enzyme 2 (ACE2) is a crucial target both in the prevention and in the therapy of COVID-19. We explored the involvement of oxidoreductive mechanisms by investigating the effects of oxidants and antioxidants on virus uptake by ACE2-expressing cells of human origin (ACE2-HEK293). The cell uptake of pseudoviruses carrying the envelope of either Delta or Omicron variants of SARS-CoV-2 was evaluated by means of a cytofluorimetric approach. The thiol N -acetyl-L-cysteine (NAC) inhibited the uptake of both variants in a reproducible and dose-dependent fashion. Ascorbic acid showed modest effects. In contrast, neither hydrogen peroxide (H
2 O2 ) nor a system-generating reactive oxygen species (ROS), which play an important role in the intracellular alterations produced by SARS-CoV-2, were able to affect the ability of either Delta or Omicron SARS-CoV-2 pseudoviruses to be internalized into ACE2-expressing cells. In addition, neither H2 O2 nor the ROS generating system interfered with the ability of NAC to inhibit that mechanism. Moreover, based on previous studies, a preventive pharmacological approach with NAC would have the advantage of decreasing the risk of developing COVID-19, irrespective of its variants, and at the same time other respiratory viral infections and associated comorbidities.- Published
- 2022
- Full Text
- View/download PDF